Anteris Technologies Ltd (ASX: AVR) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Anteris Technologies Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $360.87 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 13.88 million
Earnings per share -3.090
Dividend per share N/A
Year To Date Return 109.57%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Anteris Technologies Ltd (ASX: AVR)
Latest News

Five healthcare workers standing together and smiling.
Healthcare Shares

2 ASX healthcare shares bucking the trend to hit new highs on Friday

These healthcare shares are on form on Friday

Read more »

a group of surgeons in full surgery dress including masks, gloves and head coverings stands together with arms folded and smiling eyes as if happy with the outcome of their efforts.
Healthcare Shares

Anteris (ASX:AVR) share price soars 22% on successful human trial

The company's shares are off to a strong start this week.

Read more »

woman looking at iPhone whilst working on a laptop
Share Fallers

Why the Anteris (ASX:AVR) share price backtracked 6% today

Anteris shares slide after news of an impending share dilution.

Read more »

Young doctor raising arms in air with hands in fists celebrating a new development
Healthcare Shares

Why is the Anteris (ASX:AVR) share price surging today?

The Anteris Technologies Ltd (ASX: AVR) share price is rising today after the company announced its ComASUR Key Milestone report.

Read more »

falling healthcare asx share price Mesoblast capital raising
Share Market News

Anteris (ASX:AVR) share price drops 7% despite positive announcement

The Anteris (ASX: AVR) share price has plunged 7.6% today despite a positive announcement from the medical company.

Read more »

Dollar signs arrows pointing higher
Share Market News

The Anteris (ASX:AVR) share price is down today but has soared 150% in 3 months

The Anteris (ASX:AVR) share price exploded 150% higher over the past 3 months. Here's a summary of the latest results…

Read more »

investor looking excited at rising fortescue share price on laptop
Share Market News

Why the Anteris Technologies (ASX:AVR) share price soared 23% today

The Anteris Technologies Ltd (ASX: AVR) share price rose an incredible 23% today after an online investor presentation yesterday.

Read more »

A boy with question mark on his forehead looking up as if watching an ASX share price
Share Market News

Why the Anteris (ASX:AVR) share price will be on watch today

The Anteris Technologies (ASX:AVR) share price will be on watch this morning following the release of the company's latest results.

Read more »

AVR ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Anteris Technologies Ltd

Formerly known as Admedus Ltd (ASX: AHZ), Anteris Technologies Ltd (ASX: AVR) is a healthcare company specialising in the design and production of heart valve and tissue products.

After having sold the rights to its CardioCel® and VascuCel® patch products in 2019, the company’s main focus today is on its Adapt® BioScaffold products and the development of new heart valve replacement solutions. According to Anteris, the Adapt products are used across more than 135 medical centres globally.

In 2020, the company commenced human trials of its DurAVR™ heart valve.

The Anteris share price has been a highly disappointing performer on the ASX, losing more than 90% of its value over the past five years. The company has executed several capital raisings and has struggled with debt and cash flow issues.

AVR Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
09 Aug 2022 $26.00 $-1.16 -4.27% 35,662 $26.31 $26.31 $25.00
08 Aug 2022 $27.16 $-0.44 -1.59% 7,402 $27.90 $28.00 $26.31
05 Aug 2022 $27.60 $0.10 0.36% 7,385 $27.25 $27.88 $26.73
04 Aug 2022 $27.50 $1.40 5.36% 13,869 $26.36 $28.50 $25.99
03 Aug 2022 $26.10 $-0.19 -0.72% 9,397 $25.54 $26.61 $25.12
02 Aug 2022 $26.29 $-0.31 -1.17% 11,406 $26.64 $26.70 $25.14
01 Aug 2022 $26.60 $-0.55 -2.03% 7,999 $27.20 $27.23 $26.11
29 Jul 2022 $27.15 $1.05 4.02% 26,333 $26.00 $27.32 $26.00
28 Jul 2022 $26.10 $0.40 1.56% 11,582 $25.80 $26.10 $25.50
27 Jul 2022 $25.70 $0.61 2.43% 14,741 $25.09 $25.84 $24.00
26 Jul 2022 $25.09 $0.59 2.41% 9,013 $24.50 $25.19 $24.50
25 Jul 2022 $24.50 $-2.75 -10.09% 30,363 $26.44 $27.00 $23.71
22 Jul 2022 $27.25 $-0.20 -0.73% 10,172 $27.46 $27.89 $26.66
21 Jul 2022 $27.45 $0.95 3.58% 18,099 $26.50 $27.94 $26.40
20 Jul 2022 $26.50 $0.35 1.34% 31,394 $26.50 $26.70 $26.01
19 Jul 2022 $26.15 $-0.08 -0.30% 5,135 $26.60 $26.60 $26.02
18 Jul 2022 $26.23 $-0.59 -2.20% 5,814 $26.90 $26.90 $26.23
15 Jul 2022 $26.82 $0.82 3.15% 10,438 $25.50 $26.87 $25.50
14 Jul 2022 $26.00 $-0.83 -3.09% 34,803 $26.50 $26.50 $25.01
13 Jul 2022 $26.83 $0.03 0.11% 9,450 $26.79 $26.90 $26.50
12 Jul 2022 $26.80 $-0.90 -3.25% 14,374 $27.60 $28.00 $26.80

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
13 Jun 2022 Stephen (Steve) Denaro Issued 40 $940,000
Issue of options.
13 Jun 2022 John Seaberg Issued 80 $1,880,000
Issue of options.
13 Jun 2022 Wayne Paterson Issued 300 $7,050,000
Issue of options. As per announcement on 17-06-2022
13 Jun 2022 Wenyi Gu Issued 40 $940,000
Issue of options.
07 Mar 2022 Stephen (Steve) Denaro Buy 2 $40,039
On-market trade.
03 Dec 2021 John Seaberg Exercise 7 $56,000
Exercise of options.
03 Dec 2021 John Seaberg Buy 7 $56,000
Exercise of options. As per announcement on 07/12/2021.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Stephen (Steve) Denaro Company SecretaryNon-Executive Director Oct 2018
Mr Denaro was appointed as Non-Executive Director and Company Secretary on 31 October 2018. Mr Denaro has more than 30 years of senior level and Board level experience across publiclylisted companies; serving as Chief Financial Officer, Company Secretary and Director. He brings experience in managing compliance with finance and accounting regulatory requirements. He has managed investment acquisitions and subsequent funding (domestic and international). Mr Denaro is a resident of Brisbane, QLD, Australia.
Mr John Seaberg Non-Executive DirectorNon-Executive Chairman Oct 2014
Mr Seaberg has been an independent Non-Executive Director of Anteris Technologies Ltd since 10 October 2014. He was appointed as Deputy Chair on 16 June 2016 and Chair on 14 March 2017. From 2008 until its sale to Baxter in 2012, Mr Seaberg served as Chair of the Board of Synovis Inc (NASDAQ:SYNO), a Minneapolis based manufacturer of various medical devices and bio scaffold tissue products. From 2007 until 2014 he was Founder, Chair and CEO of NeoChord Inc., a venture capital-backed company commercialising technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, Mr Seaberg served at Guidant Corp (subsequently acquired by Boston Scientific Corp) where he served in various executive level positions including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In 1991, Mr Seaberg was co-founder of ACIST Medical and served as its first President and CEO. Mr Seaberg is a resident of Minneapolis, Minnesota, United States of America. He is a member of Risk Management Committee.
Mr Wayne Paterson Managing DirectorChief Executive Officer Feb 2016
Mr Paterson has been a Director of Anteris Technologies Ltd since 10 October 2014. Mr Paterson has held numerous senior positions in multi-national pharmaceutical companies and has lived in seven countries during the past 20 plus years. Throughout his career, he has been responsible for building and managing multi-billion dollar businesses throughout the world, including mergers, integrations, acquisitions and major restructures as President and CEO. From 2005 to 2013 Mr Paterson held senior positions at Merck KGaA, most recently as President of Europe, Canada and Australia. Prior to this, Mr Paterson was President of Emerging Markets, President of Japan and Global Head of Cardiovascular Medicine. Between 1999 and 2005, Mr Paterson served at Roche Pharmaceuticals where he was most recently Head of Pharmaceuticals in Roche's South Korean operation. He also served as Head of Commercial Operations for Roche China based in Shanghai. Mr Paterson is an Australian national and resides in Minneapolis, Minnesota, United States of America.
Dr Wenyi Gu Non-Executive Director Oct 2018
Dr Gu currently works as Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland (UQ), where he began his post-doctoral work in 2001. He held a Peter Doherty Fellowship (2006-2009) and was supported by the National Health and Medical Research Council (NHMRC) to work at Harvard Medical School, Harvard University as a visiting research fellow. Before engaging in nanomedicine (focusing on drug delivery and cancer therapy), he worked on RNAi-based gene therapy for several years at Translation Research Institute (TRI). Dr Gu's research has been published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. Dr Gu is a resident of Brisbane, QLD, Australia.
Mr Matthew McDonnell Chief Financial Officer
Mr David St Denis Chief Operating Officer

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Perceptive Life Sciences Master Fund Ltd 1,840,000 13.56%
CS Third Nominees Pty Limited <Hsbc Cust Nom Au Ltd 13 A/C> 1,310,115 9.66%
HSBC Custody Nominees (Australia) Limited A/C 2 876,687 6.46%
Citicorp Nominees Pty Limited 567,794 4.19%
Bnp Paribas Noms Pty Ltd <Global Markets Drp> 417,295 3.08%
Hunter Capital Advisors P/L 411,214 3.03%
Mr Patrick Chew 283,055 2.09%
Mr Ricky Steven Neumann 244,314 1.80%
Hsbc Custody Nominees (Australia) Limited 201,207 1.48%
Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 189,221 1.39%
Amedan Pty Ltd 111,195 0.82%
Dr Gary Owen Rooke 111,000 0.82%
Mishtalem Pty Ltd 103,000 0.76%
Mr Daniel Bernard Clough 100,000 0.74%
Superior Coatings (Aust) Pty Ltd 100,000 0.74%
Evolution Capital Pty Ltd 95,000 0.70%
Bnp Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 89,033 0.66%
Mdm Leby Hwang 84,000 0.62%
Sisu International Pty Ltd 82,500 0.61%
Sean Barrett Pty Ltd <Super Fund A/C> 80,000 0.59%